Hera Health Solutions
Hera Health Solutions Inc. is a pharmaceutical device company specializing in the research, development, and commercialization of long acting treatments through proprietary bioerodible drug delivery implants. The company aims to revolutionize long-acting drug delivery with innovative biodegradable implants that eliminate the painful, risky, and costly removal procedures of current drug implants. Hera's mission is to provide accessible, sustainable medicine worldwide, leveraging nanotechnology, bioerodible materials, and advanced manufacturing processes to improve patient outcomes and healthcare accessibility.
Industries
Nr. of Employees
small (1-50)
Hera Health Solutions
Memphis, Tennessee, United States, North America
Products
Biodegradable subcutaneous contraceptive implant (etonogestrel formulation)
A matchstick-sized, bioerodible subcutaneous implant intended to elute a contraceptive hormone over multi-year periods and fully resorb to avoid a removal procedure.
Biodegradable subcutaneous buprenorphine-releasing implant
An investigational biodegradable subcutaneous implant designed to deliver buprenorphine over an extended period to support opioid-use-disorder and pain management indications.
Biodegradable subcutaneous deslorelin-releasing implant (peptide/hormone delivery)
An investigational biodegradable polymer-based subcutaneous implant designed to provide sustained release of a gonadotropin-releasing hormone (GnRH) superagonist for veterinary or other indicated uses.
Biodegradable subcutaneous contraceptive implant (etonogestrel formulation)
A matchstick-sized, bioerodible subcutaneous implant intended to elute a contraceptive hormone over multi-year periods and fully resorb to avoid a removal procedure.
Biodegradable subcutaneous buprenorphine-releasing implant
An investigational biodegradable subcutaneous implant designed to deliver buprenorphine over an extended period to support opioid-use-disorder and pain management indications.
Biodegradable subcutaneous deslorelin-releasing implant (peptide/hormone delivery)
An investigational biodegradable polymer-based subcutaneous implant designed to provide sustained release of a gonadotropin-releasing hormone (GnRH) superagonist for veterinary or other indicated uses.
Services
Technology licensing for drug delivery platform
Licensing of a nanotechnology-enabled biodegradable implant platform to regional or pharmaceutical partners for co-development and commercialization.
Collaborative formulation and proof-of-concept development
Partnership-based formulation development including bench validation and proof-of-concept studies for implantable therapeutics.
Preclinical and clinical program support for implantable therapeutics
Program support spanning bench validation, preclinical studies, and clinical trial stages for implantable drug products.
Technology licensing for drug delivery platform
Licensing of a nanotechnology-enabled biodegradable implant platform to regional or pharmaceutical partners for co-development and commercialization.
Collaborative formulation and proof-of-concept development
Partnership-based formulation development including bench validation and proof-of-concept studies for implantable therapeutics.
Preclinical and clinical program support for implantable therapeutics
Program support spanning bench validation, preclinical studies, and clinical trial stages for implantable drug products.
Expertise Areas
- Long-acting implantable drug delivery
- Biodegradable polymer materials for implants
- Electrospinning and nanofiber scaffold engineering
- Sustained-release formulation development
Key Technologies
- Electrospinning
- Nanofiber scaffolds
- Biodegradable polymer implants
- Nanotechnology-enabled drug delivery